Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study

Schizophrenia Research

Volumn 170, Issue 2-3, 2016, Pages 245-251

  Lodhi, Rohit J ^a   Masand, Salaj ^b   Malik, Amna ^c,e   Shivakumar, Kuppuswami ^d,e   McAllister, Victoria D M ^e   O'Keane, Veronica ^f   Young, Leah C ^a   Heald, Adrian H ^g   Sherwood, Roy A ^h   Aitchison, Katherine J ^a,e,i  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c Lewisham Primary Care Psychological Therapies Service   (United Kingdom)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^e SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Aripiprazole; Bone markers; Ntxc

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ARIPIPRAZOLE; BIOLOGICAL MARKER; ESTROGEN; NEUROLEPTIC AGENT; NTX PROTEIN; PROLACTIN; TESTOSTERONE; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; PAX5 PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; URINE LEVEL; ADOLESCENT; BIPOLAR DISORDER; BLOOD; BONE REMODELING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOTIC DISORDERS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BIOMARKERS; BIPOLAR DISORDER; BONE REMODELING; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PAX5 TRANSCRIPTION FACTOR; PROLACTIN; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TESTOSTERONE; YOUNG ADULT;

EID: 84958859802     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.12.007     Document Type: Article

References (43)

1. Abel K.M., Heatlie H.F., Howard L.M., Webb R.T. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. J. Clin. Psychiatry 2008, 69:1398-1403.
2. Aitchison K.J., Mir A., Shivakumar K., McAllister V.D., O'Keane V., McCrone P. Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. J. Psychopharmacol. 2011, 25(5):675-684.
3. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
4. Bishop J.R., Rubin L.H., Reilly J.L., Pavuluri M.N., Sweeney J.A. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther. Adv. Psychopharmacol. 2012, 2(3):95-102.
5. Body J.J., Bergmann P., Boonen S., Boutsen Y., Bruyere O., Devogelaer J.P., Goemaere S., Hollevoet N., Kaufman J.M., Milisen K., Rozenberg S., Reginster J.Y. Non-pharmacological management of osteoporosis: a consensus of the Belgian bone club. Osteoporos. Int. 2011, 22(11):2769-2788.
6. Bolton J.M., Targownik L.E., Leung S., Sareen J., Leslie W.D. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J. Clin. Psychopharmacol. 2011, 31(1):56-60.
7. Breslow N.E., Clayton D.G. Approximate inference in generalized linear mixed models. J. Am. Stat. Assoc. 1993, 88(421):9-25.
8. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., Ingenito G.G., Aripiprazole Study, G. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003, 166(4):391-399.
9. Croxtall J.D. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012, 26(2):155-183.
10. De Hert M., Correll C.U., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., Detraux J., Gautam S., Moller H.J., Ndetei D.M., Newcomer J.W., Uwakwe R., Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10(1):52-77.
11. Di Giovanni G., Roy B.D., Gammage K.L., Mack D., Klentrou P. Associations of oral contraceptive use and dietary restraint with bone speed of sound and bone turnover in university-aged women. Appl. Physiol. Nutr. Metab. 2008, 33(4):696-705.
12. Diem S.J., Joffe H., Larson J.C., Tsai J.N., Guthrie K.A., LaCroix A.Z., Ensrud K.E., Freeman E.W., Leder B.Z. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J. Clin. Endocrinol. Metab. 2014, 99(9):E1732-E1737.
13. Glover S.J., Garnero P., Naylor K., Rogers A., Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42(4):623-630.
14. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(Suppl. 1):53-67.
15. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br. J. Psychiatry 2007, 190:129-134.
16. Hummer M., Malik P., Gasser R.W., Hofer A., Kemmler G., Moncayo Naveda R.C., Rettenbacher M.A., Fleischhacker W.W. Osteoporosis in patients with schizophrenia. Am. J. Psychiatry 2005, 162(1):162-167.
17. Ju H.S., Leung S., Brown B., Stringer M.A., Leigh S., Scherrer C., Shepard K., Jenkins D., Knudsen J., Cannon R. Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 1997, 43(9):1570-1576.
18. Kinon B.J., Liu-Seifert H., Stauffer V.L., Jacob J. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin. Schizophr. Relat. Psychoses 2013, 7(3):115-123.
19. Kishimoto T., De Hert M., Carlson H.E., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr. Opin. Psychiatry 2012, 25(5):415-429.
20. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20(6):612-627.
21. Lee T.Y., Chung M.Y., Chung H.K., Choi J.H., Kim T.Y., So H.S. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig. 2010, 7(4):278-284.
22. Leucht S., Burkard T., Henderson J., Maj M., Sartorius N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr. Scand. 2007, 116(5):317-333.
23. Leucht S., Samara M., Heres S., Patel M.X., Furukawa T., Cipriani A., Geddes J., Davis J.M. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr. Bull. 2015, 41(6):1397-1402.
24. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br. J. Psychiatry 2004, 184:503-508.
25. Mir A., Shivakumar K., Williamson R.J., McAllister V., O'Keane V., Aitchison K.J. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J. Psychopharmacol. 2008, 22(3):244-253.
26. Misra M., Papakostas G.I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J. Clin. Psychiatry 2004, 65(12):1607-1618. (quiz 1590, 1760-1601).
27. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J. Clin. Psychopharmacol. 2005, 25(1):26-31.
28. Patel M.X., Arista I.A., Taylor M., Barnes T.R. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr. Res. 2013, 149(1-3):141-148.
29. Renn J.H., Yang N.P., Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet. Disord. 2010, 11:35.
30. Rey-Sanchez P., Lavado-Garcia J.M., Canal-Macias M.L., Gomez-Zubeldia M.A., Roncero-Martin R., Pedrera-Zamorano J.D. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum. Psychopharmacol. 2009, 24(1):49-54.
31. Schafer A.L., Vittinghoff E., Ramachandran R., Mahmoudi N., Bauer D.C. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos. Int. 2010, 21(3):439-445.
32. Seibel M.J., Lang M., Geilenkeuser W.J. Interlaboratory variation of biochemical markers of bone turnover. Clin. Chem. 2001, 47(8):1443-1450.
33. Singer F.R., Eyre D.R. Using biochemical markers of bone turnover in clinical practice. Cleve. Clin. J. Med. 2008, 75(10):739-750.
34. Stransky M., Rysava L. Nutrition as prevention and treatment of osteoporosis. Physiol. Res. 2009, 58(Suppl. 1):S7-S11.
35. Stubbs B., De Hert M., Sepehry A.A., Correll C.U., Mitchell A.J., Soundy A., Detraux J., Vancampfort D. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr. Scand. 2014, 130(6):470-486.
36. Stubbs B., Gaughran F., Mitchell A.J., De Hert M., Farmer R., Soundy A., Rosenbaum S., Vancampfort D. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen. Hosp. Psychiatry 2015, 37(2):126-133.
37. Sugawara N., Yasui-Furukori N., Fujii A., Saito M., Sato Y., Nakagami T., Tsuchimine S., Kaneko S. No association between bone mass and prolactin levels among patients with schizophrenia. Hum. Psychopharmacol. 2011, 26(8):596-601.
38. Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines in Psychiatry 2015, Wiley Blackwell, London. 12th ed.
39. Vasikaran S., Eastell R., Bruyere O., Foldes A.J., Garnero P., Griesmacher A., McClung M., Morris H.A., Silverman S., Trenti T., Wahl D.A., Cooper C., Kanis J.A., Group I.-I.B.M.S.W. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 2011, 22(2):391-420.
40. Wheater G., Elshahaly M., Tuck S.P., Datta H.K., van Laar J.M. The clinical utility of bone marker measurements in osteoporosis. J. Transl. Med. 2013, 11:201.
41. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
42. Wu H., Deng L., Zhao L., Zhao J., Li L., Chen J. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int. J. Endocrinol. 2013, 2013:167138.
43. Wyszogrodzka-Kucharska A., Rabe-Jablonska J. Osteoporosis risk factors among patients with schizophrenia. Przegl. Lek. 2006, 63(3):134-138.